national pharmaceutical pricing authority :price ...€¦ · nppa in its 132th authority meeting...

National Pharmaceutical Pricing Authority : Price Notification Page 2of2

any) for the specified pack and packs of similar strength, and companies cannot claim exemption on anground therefrom, unless specifically permitted by the Government/NPPA through an order.

(b) The companies / manufacturers may added taxes only if they have paid actually to the Government 01the price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), th<same may be intimated to the NPPA in the Form-V of DPCO, 1995.

•(c) For different packing material used or, different drug delivery systems or any other speciefeatures/forms claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicabhunless the companiesapproaches NPPA for specific price approvals for its formulations.

(d) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorilimplemented by the manufacturing /marketing company notwithstanding its status of compliance cconditions for such formulation pack under the Drugs and Cosmetics Act, 1940.

(e) The manufacturer and marketing company for the above said formulation shall be required to take th<requisite prior approval from the competent Authority for any change in the composition of the abovisaid formulation with written prior intimation to the National Pharmaceutical Pricing Authority.

(f) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiliniprice by a factor of 1.04 as per the existing rates of excise duty and VAT.

(g) The MRP arrived as above shall besubject to payment ofGovernment levies / taxes as applicable amnecessary adjustment in the factor of 1.04 shall necessarily be required to be made by thtmanufacturer/marketing company, whenever the existing rate of excise duty and/or VAT undergoes ;change, subject to the condition that the excise duty and/orVAT so calculated shall in no case exce&the actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable aper the factor of 1.04. The manufacturer/marketing company shall be specifically liable to ensure thicompliance of this condition.

(h) Any other formulation / composition not covered in the above table that has any one ofthe schedule*drugs in Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respectiviserial number of the table, as the case may be, unless the manufacturer has got hereafter specifiprice fixed by the NPPA for that formulation.

(i) The manufacturer or marketing company not complying with the ceiling prices and conditions specifi©in notes hereinabove within 15 days from the date of above said notification, shall be liable to deposovercharged amount along with the interest under the provisions ofthe DPCO, 1995 read with the E(Act, 1955.

(j) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(sissued prior to this date of notification stand automatically withdrawn.

PN/132/2013/F

F. No. 8(41)/2012/D.P./NPPA-Div.l

(MANMOHAN KAURDeputy Directo

National Pharmaceutical Pricing Authorit;

Top of the Page | Home

http://www.nppaindia.nic.in/ceiling/pressl0junel3/sol540e-14-6-13.html 18-Jun-13

National Pharmaceutical Pricing Authority : Price Notification

\ %> Price Notifications

(Published in Part II, Section 3, Sub Section (ii) of theGazette of India Extraordinary)

Government of IndiaMinistry of Chemicals and Fertilizers

Department of Pharmaceuticals(National Pharmaceuticals Pricing Authority)

Page 1 of2

2-2^

New Delhi, the 14th June, 201:

ORDER

S.O.1541(E) - In exercise of the powers, conferred by sub-paragraphs (1) and (2) of paragraph 9 amparagraph 11 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th Septembei1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of thuOrder of the Government of India in the Ministry of Chemicals and Fertilizers, (National PharmaceuticsPricing Authority) No. S.O. 2735(E), dated 16th November, 2012, in so far as it relates to formulation packmentioned in the table below, except in respect of things done or omitted to be done before suclsupersession, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5of the table below as ceiling prices exclusive of excise duty and local tax, if any, and in column (6) of the tabl<below as Equivalent MRP inclusive of excise duty and education cess, sales taxA/AT of each of th«Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the strengtland pack size specified respectively in the corresponding entries in columns (3) and (4) thereof:

NPPA in its 132th Authority Meeting held on 16.05.2013 duly considered the aforesaid price fixation ordeand approved the prices of Human Insulin Injection imported finished form formulations having domesticindigenous substitute as per the guidelines approved in 121st Authority Meeting held on 22.7.2011 for sue!imported formulations. Accordingly, prices for Human Insulin Injection imported finished form were approve*in "public interest" under various provisions of the DPCO, 1995, in order to ensure fair amaffordable/reasonable price to consumer public.

Table

SI.

No.Name of the Formulation Strength Pack Size

CeilingPrice

(Rs.)

EquivalentMRP*

(inclusiveof all

taxes)(Rs.)

(1) (2) (3) (4) (5) (6)

Each ml contains

1 Human Insulin InjectionInsulin Human -40 IU

(Human Insulin ofrecombinant DNA Origin)

10ml Vial 160.26 166.67



10ml Vial 369.34 384.11



3ml Cartridge 200.01 208.01

*Subject to actual payment of Government levies/taxes, as applicable.

NOTE:

http://www.nppaindia.nic.in/ceiling/press1Ojune13/so1541e-14-6-13 .html 18-Jun-13

National Pharmaceutical Pricing Authority : Price Notification Page 2 of2

(a) The prices fixed are the maximum retail prices in column (6) (inclusive of excise duty and local taxesany) for the specified pack and packs of similar strength, and companies cannot claim exemption oiany ground therefrom, unless specifically permitted by the Government/NPPA through an order.

(b) The companies / manufacturers may added taxes only if they have paid actually to the Government othe price mentioned in the column (5). If there is any variation in the MRP (inclusive of the taxes), th«same may be intimated to the NPPA in the Form-V of DPCO, 1995.

(c) For different packing material used or, different drug delivery systems or any other speciafeatures/forms claimed, the ceiling prices, as specified in Column No. 5 above, shall be applicabhunless the companies approaches NPPA for specific price approvals for its formulations.

(d) The prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorilimplemented by the manufacturing /marketing company notwithstanding its status of compliance cconditionsfor such formulation pack under the Drugs and Cosmetics Act, 1940.

,(e) The manufacturer and marketing company for the above said formulation shall be required to take thirequisite prior approval from the competent Authority for any change in the composition of the abovisaid formulation with written prior intimation to the National Pharmaceutical Pricing Authority.

(f) The ceiling price arrived on the basis of above shall not exceed the MRP by multiplying the ceiliniprice by a factor of 1.04 as per the existing rates of excise duty and VAT.

(g) The MRP arrived as above shall be subject to payment of Government levies / taxes as applicable amnecessary adjustment in the factor of 1.04 shall necessarily be required to be made by thimanufacturer/marketing company, wheneverthe existing rate of excise duty and/or VAT undergoes ;change, subject to the condition that the excise duty and/or VAT so calculated shall in no case exceeithe actual excise duty and/or VAT paid by the manufacturer/marketing company or as applicable aper the factor of 1.04. The manufacturer/marketing company shall be specifically liable to ensure th<compliance of this condition.

(h) Any other formulation / composition not covered in the above table that has any one of the schedule*drugs in Column No. (3) as one of its ingredients, it shall be subject to the price ceiling at respectiviserial number of the table, as the case may be, unless the manufacturer has got hereafter specifiprice fixed by the NPPA for that formulation.

(i) The manufactureror marketing company not complying with the ceiling prices and conditions specifieiin notes hereinabove within 15 days from the date of above said notification, shall be liable to deposovercharged amount along with the interest under the provisions of the DPCO, 1995 read with the E(Act, 1955.

(j) Consequent to the issue of ceiling price of the formulation pack(s) in this notification, the price order(sissued prior to this date of notification stand automatically withdrawn.

P N/132/2013/F

F. No. 8(41)/2013/D.P./NPPA-Div.l

(MANMOHAN KAURDeputy Directo

National Pharmaceutical Pricing Authority


http://www.nppaindia.nic.in/ceiling/press1Ojune13/so1541e-14-6-13 .html 18-Jun-13


Price Notifications


Government of India

Ministry of Chemicals and FertilizersDepartment of Pharmaceuticals

(National Pharmaceuticals Pricing Authority)

Page 1 of2

^2

New Delhi, the 14thJune, 2013

ORDER

S.O. 1542(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive

,of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) of the said Table with the unit specified respectively in the corresponding entries in columns (4)thereof:

Table

SI. No.Name of the Schedule

FormulationStrength Unit

CeilingPrice

(Rs.)

(1) (2) (3) (4) (5)

1 Halothane Vaporizer Inhalation - 1 ml 5.87

NOTE :

(a) The manufacturers of above mentioned scheduled formulations having maximum retail price higherthan the ceiling price specified in column (5) of the table hereinabove, shall revise the MRP to anamount not exceeding the ceiling price plus local taxes, wherever applicable in accordance withparagraph 13 (1) and 24 of the DPCO.2013.

(b) The manufacturers may add local taxes only if they have paid actually to the Government on theceiling price mentioned in the column (5) of the above table.

(c) The ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inaccordance with the ceiling price specified in column (5) of the above table as per provisionscontained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issuea price list in Form-V as per the paragraph 24 (2) of the DPCO, 2013.

(d) All the existing manufacturers of above mentioned scheduled formulations having MRP lower thanthe ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shallcontinue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

(e) Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO.2013 then suchexisting manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I asspecified under schedule-ll of the DPCO, 2013.

'(f) The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, inrespect of production / import and sale of scheduled formulation in Form-Ill of scheduled-ll of theDPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall

http://www.nppaindia.nic.in/ceiling/press14june13/so1542e-14-6-13.html 18-Jun-13

National Pharmaceutical Pricing Authority :Price Notification Page 2of 2

'furnish information to the NPPA, in respect of discontinuation of the production and / or import of schedulesformulation in Form-IV of scheduled-ll of the DPCO, 2013 at least six months prior to the indenteddate of discontinuation.

(q) The manufacturer not complying with the ceiling price and notes specified hereinabove in thisnotification shall be liable to deposit overcharged amount along with the interest thereon under theprovisions of the Drugs (Prices Control) Order, 2013 read with the Essential Commodities Act, 1955.

(h) Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) ofthe above table in this notification, the price order(s) if any, issued prior to the above said date ofnotification, stand withdrawn.

PN/133/1/2013/F

F. No. 8(1)/2013/D.P./NPPA-Div.ll

(MANMOHAN KAUR)Deputy Director





Price Notifications


Government of India



Page 1 of2

2-V

New Delhi, the 14th June, 2013

ORDER

S.0.1543(E) - In exercise ofthe powers, conferred by paragraph 4, 11 and 14ofthe Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Governmentof India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the pricesas specified in column (5) of the table herein below as ceiling prices exclusiveoflocal tax applicable, if any in respectofthe Scheduled formulations specified in the corresponding entry incolumn (2) ofthe said Table with the strength and unit specified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table



CeilingPrice

(Rs.)

(1) (2) (3) (4) (5)1 Ketamine Hydrochloride Injection 50mg/ml 1 ml 10.46

NOTE:

(a) The manufacturers ofabove mentioned scheduled formulations having maximum retail price higherthan the ceiling price specified in column (5) of the table hereinabove, shall revise the MRP to anamount not exceeding the ceiling price plus local taxes, wherever applicable in accordance withparagraph 13 (1) and 24 of the DPCO.2013.


(c) The ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inaccordance with the ceiling price specified in column (5) of the above table as per provisionscontained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturershall issuea price list in Form-V as per the paragraph 24 (2) of the DPCO, 2013.

(d) All the existing manufacturers of above mentioned scheduled formulations having MRP lower thanthe ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shallcontinue to maintain theexisting MRP in accordance with paragraph 13(2) ofthe DPCO, 2013.

(e) Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) ofDPCO,2013 then suchexisting manufacturer shall apply for prior price approval of such new drug to the NPPA in Form Iasspecified under schedule-ll of the DPCO, 2013.

(f) The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA inrespect of production / import and sale of scheduled formulation in Form-Ill of scheduled-ll of theDPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall



furnish information to the NPPA, in respect of discontinuation of the production and / or import of schedulesformulation in Form-IV of scheduled-ll of the DPCO, 2013 at least six months prior to the indenteddate of discontinuation.

(g) The manufacturer not complying with the ceiling price and notes specified hereinabove in thisnotification, shall be liable to deposit overcharged amount along with the interest thereon under theprovisions ofthe Drugs (Prices Control) Order, 2013 read with the Essential Commodities Act, 1955.


PN/133/1/2013/F







Price Notifications


Government of India



Page 1 of2


ORDER

S.0.1544(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein belowas ceiling prices exclusiveof local tax applicable, ifany in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) of the said Table with the strength and unitspecified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table



CeilingPrice

(Rs.)

(1) (2) (3) (4) (5)1 Thiopentone Sodium Injection 0.5gm/pack Each Pack 41.67

NOTE:



(c) The ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inaccordance with the ceiling price specified in column (5) of the above table as per provisionscontained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issuea price list in Form-Vas per the paragraph 24 (2) of the DPCO, 2013.


(e) Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO.2013 then suchexisting manufacturer shall apply for prior price approval ofsuch new drug to the NPPA in Form Iasspecified under schedule-ll of the DPCO, 2013.

(f) The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA, inrespect of production / import and sale of scheduled formulation in Form-Ill of scheduled-ll of theDPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall






PN/133/1/2013/F






National Pharmaceutical PricingAuthority : PriceNotification

£t Price Notifications




Page 1 of2

2Jb


ORDER

,S.0.1545(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E)dated the 30th May, 2013 issued by the Government of India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) herebyfixes the prices as specified in column (5) of the table herein belowas ceiling prices exclusiveof local taxapplicable, if any in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) of the said Table with the strength and unit specified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table



CeilingPrice

(Rs.)

(1) (2) (3) (4) (5)1 Propofol Injection 1% Oil Suspension Each Pack 7.94

NOTE:



(c) The ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inaccordance with the ceiling price specified in column (5) of the above table as per provisionscontained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issuea price list in Form-Vas per the paragraph 24 (2) of the DPCO, 2013.

(d) All the existing manufacturers ofabove mentioned scheduled formulations having MRP lower thanthe ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shallcontinue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.







(h) Consequent to the issue ofceiling price of the scheduled formulation as specified in column (2) ofthe above table in this notification, the price order(s) if any, issued prior to the above said date ofnotification, stand withdrawn.

PN/133/1/2013/F






National Pharmaceutical Pricing Authority: Price Notification Page 1 of2

Price Notifications




2.7


ORDER

S.0.1546(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusiveof local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) of the said Table with the strength and unit specified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table


FormulationStrength. Unit

CeilingPrice

(Rs.)

(1) (2) (3) (4) (5)

1Lignocaine Hydrochloride+Adrenaline Injection 1%+1:200,000/pack Each Pack 0.68

NOTE

(a)

(b)

(c)

(d)

(e)

(f)

The manufacturers of above mentioned scheduled formulations having maximum retail price higherthan the ceiling price specified in column (5) of the table hereinabove, shall revise the MRP to anamount not exceeding the ceiling price plus local taxes, wherever applicable in accordance withparagraph 13 (1) and 24 of the DPCO.2013.

The manufacturers may add local taxes only if they have paid actually to the Government on theceiling price mentioned in the column (5) of the above table.

The ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inaccordance with the ceiling price specified in column (5) of the above table as per provisionscontained in paragraph 11 ofthe Drugs (Prices Control) Order, 2013. The manufacturer shall issuea price list in Form-V as perthe paragraph 24(2) ofthe DPCO, 2013.

All the existing manufacturers of above mentioned scheduled formulations having MRP lower thanthe ceiling price specified in column (5) in the above table plus local taxes as applicable if any shallcontinue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013'.

Where an existing manufacturer of scheduled formulation with dosage or. strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO 2013 then suchexisting manufacturer shall apply for prior price approval of such new druq to the NPPA in Form Iasspecified under schedule-lIof the DPCO, 2013.

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA inrespect of production / import and sale of scheduled formulation in Form-Ill of scheduled-ll of the

http://www.nppaindia.nic.in/ceiling/pressl4june13/so1546e-14-6-13.html 18-Jun-13

National Pharmaceutical Pricing Authority : PriceNotification Page 2 of 2

DPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall furnishinformation to the NPPA, in respect of discontinuation of the production and / or import of schedulesformulation in Form-IV of scheduled-ll of the DPCO, 2013 at least six months prior to the indenteddate of discontinuation.

(g) The manufacturer not complying with the ceiling price and notes specified hereinabove in thisnotification, shall be liable to deposit overcharged amount along with the interest thereon under theprovisions of the Drugs (Prices Control) Order, 2013 read with the Essential Commodities Act, 1955.


PN/133/1/2013/F






National Pharmaceutical Pricing Authority : Price Nott'ficatfon Page 1 of2

Price Notifications

(Published in Part II, Section 3, Sub Section (ii) oftheGazette of India Extraordinary)



2^


ORDER

S'?"15Î(E) "ln exercise of the Powers, conferred by paragraph 4, 11 and 14 of the Druas (Prices ControhOrder 20 3 read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Governmenti onndPaTn heNPPA7hl?u?vLCcaShand FertiNZerS' *e,Nati0nal Pharêutical Pricing Authority (hereinafte eferred asnnî t V? mhe,PriC6S aS SpeClfied in COlumn (5) of the table nerein below asceiling prices exclusive.of local tax applicable if any in respect of the Scheduled formulations specified in the corresponding entry inthereof *'* ^ ""'* specified resPective'y in the corresponding entries in columns (4)

Table

SI. No. Name of the ScheduleFormulation Strength Unit

CeilingPrice

(Rs.)(1) (2) (3) (4) (5)

EMLA Cream 1gm 20.08

NOTE

(a)

(b)

(c)

(d)

(e)

'(f)

Il!fnTnUfartUrerS °f ab0V! mentioned scheduled formulations having maximum retail price higherthan the ceiling price specified in column (5) of the table hereinabove, shall revise the MRP to an

paTgrapf^^ '0Cal ^^ Wher6Ver aPP'iCable in aCC°rdanCe With

^^^^^^^X^^^ aCtUa"V t0 the ^-rnment on theThe ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inaccordance with the ceiling price specified in column (5) of the above table L per provisionscontained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacture shalTSueaprice list in Form-V as per the paragraph 24 (2) of the DPCO, 2013. ldnuraciurer snail issue

All the existing manufacturers of above mentioned scheduled formulations having MRP lower thanthe ceilmg price specified in column (5) in the above table plus local taxes as applicable i a™ Scontinue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2(u) of DPCO 2013 then suchexisting manufacturer shall apply for prior price approval of such new drug to the NPPA in Form Iasspecified under schedule-ll ofthe DPCO, 2013.

Tr«n^nU?CtULerSt°f 3b0Ve Said scneduled formulatiori shall furnish quarterly return to the NPPA inDPCO 201T AnTl TT 3nd falt°f SChedUled formulation in Form-'» ofsêdu edTofiheDPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shaH

http://www.nppaindia.nic.in/ceiling/press14june13/so1547e-14-6-13.html18-Jun-13


•furnish information to the NPPA, in respect ofdiscontinuation of the production and / or import of schedulesformulation in Form-IV of scheduled-ll of the DPCO, 2013 at least six months prior to the indenteddate of discontinuation.



PN/133/1/2013/F






National Pharmaceutical Pricing Authority :>Price Notification Page 1 of2

/% Price Notifications




2*


ORDER

S.0.1548(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusiveof local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) of the said Table with the strength and unit specified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table


Formulation Strength UnitCeilingPrice

(Rs.)(1) (2) (3) (4) (5)

1 Atropine Sulphate Injection 0.6mg / ml 1 ml 4.01

NOTE

(a)

(b)

(c)

(d)

(e)

(f)


The manufacturers may add local taxes only if they have paid actually to the Government on theceiling price mentioned in the column (5) ofthe above table.

The ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inaccordance with the ceiling price specified in column (5) of the above table as per provisionscontained in paragraph 11 ofthe Drugs (Prices Control) Order, 2013. The manufacturer shall issuea price list in Form-V as perthe paragraph 24 (2) ofthe DPCO, 2013.

All the existing manufacturers of above mentioned scheduled formulations having MRP lower thanthe ceiling price specified in column (5) in the above table plus local taxes asapplicable if any shallcontinue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO 2013 then suchexisting manufacturer shall apply for prior price approval of such new drug to the NPPA in Form Iasspecified underschedule-ll of the DPCO, 2013.

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA innorn ™fo°dAUCt,0n 'imp0rt and Sale of scheduled formulation in Form-Ill of scheduled-ll of theDPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall



furnish information to the NPPA, in respectofdiscontinuation of the production and / or import of schedulesformulation in Form-IV of scheduled-ll of the DPCO, 2013 at least six months prior to the indenteddate of discontinuation.



PN/133/1/2013/F







Price Notifications




SO


ORDER

S.0.1549(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in meMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusiveof local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) ofthe said Table with the strength and unit specified respectively in the correspondinq entries incolumns (3) and (4) thereof:

Table



CeilingPrice

(Rs.)

(1) (2) (3) (4) (5)1 Diazepam Injection 5mg/ml 1 ml 5.59

NOTE

(a)

(b)

•(c)

(d)

(e)

(0



The ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inaccordance with the ceiling price specified in column (5) of the above table as per provisionscontained in paragraph 11 ofthe Drugs (Prices Control) Order, 2013. The manufacturer shall issuea price list in Form-V as per the paragraph 24 (2) ofthe DPCO, 2013.

All the existing manufacturers of above mentioned scheduled formulations having MRP lower thanthe ceiling price specified in column (5) in the above table plus local taxes as applicable if any shallcontinue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO 2013 then suchexisting manufacturer shall apply for prior price approval ofsuch new druq to the NPPA in Form Iasspecified under schedule-ll of the DPCO, 2013.

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA inS °LProductlon ' imP°rt and sale of scheduled formulation in Form-Ill of scheduled-ll of theDPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall


National Pharmaceutical Pricing Authority : Price Notification Page 2 of 2


•(g) The manufacturer not complying with the ceiling price and notes specified hereinabove in thisnotification, shall be liable to deposit overcharged amount along with the interest thereon under theprovisions of the Drugs (Prices Control) Order, 2013 read with the Essential Commodities Act, 1955.


PN/133/1/2013/F






National Pharmaceutical Pricing Authority:; Price Notification Page 1 of2

3/Price Notifications





ORDER

S.0.1550(E> - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)•Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theSS?.. CL.hemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices asspecified in column (5) of the table herein below asceiling prices exclusiveof local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry incoumn (2) of the said Table with the strength and unit specified respectively in the correspondinq entries incolumns (3) and (4) thereof: a

Table


Formulation Strength, UnitCeilingPrice

(Rs.)d) (2) (3) (4) (5)

1 Midazolam Injection 1mg/ml 1ml 5.79

NOTE:

.(a)

(b)

(c)

(d)

(e)

(f)


The manufacturers may add local taxes only if they have paid actually to the Government on theceiling price mentioned in the column (5)of the above table.

The ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inaccordance with the ceiling price specified in column (5) of the above table as per provisionscontained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issuea price list in Form-V as perthe paragraph 24 (2) ofthe DPCO, 2013.

All the existing manufacturers of above mentioned scheduled formulations having MRP lower thanthe ceiling price specified in column (5) in the above table plus local taxes asapplicable if any shallcontinue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO 2013 then suchexisting manufacturer shall apply for prior price approval of such new drug to the NPPA in Form Iasspecified under schedule-ll ofthe DPCO, 2013.

Til! ™rU?CtU[frS,°f ab0Ve Said scneduled formulation shall furnish quarterly return to the NPPA innprn ? 1TdiUCtl0n ' imp°rt and sa,e of scneduled formulation in Form-Ill of scheduled-ll of theDPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall



furnish information to the NPPA, in respect ofdiscontinuation ofthe production and / or import ofschedulesformulation in Form-IV of scheduled-ll of the DPCO, 2013 at least six months prior to the indenteddate of discontinuation.



PN/133/1/2013/F






NationalPharmaceutical Pricing Authority :> Price Notification

3* Price Notifications




Page 1 of2

32L


ORDER

S.0.1551(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusiveof local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) of the said Table with the strength and unitspecified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table



CeilingPrice

(Rs.)

(D (2) (3) (4) (5)1 Midazolam Injection 5mg/ml 1ml 24.78

NOTE:

(a) The manufacturers of above mentioned scheduled formulations having maximum retail price higherthan the ceiling price specified in column (5) of the table hereinabove, shall revise the MRP to anamount not exceeding the ceiling price plus local taxes, wherever applicable in accordance withparagraph 13 (1) and 24 of the DPCO,2013.


(c) The ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inaccordance with the ceiling price specified in column (5) of the above table as per provisionscontained in paragraph 11 of the Drugs (Prices Control) Order, 2013 The manufacturer shall issuea price list in Form-Vas per the paragraph 24 (2) of the DPCO, 2013.

(d) All the existing manufacturers of above mentioned scheduled formulations having MRP lower thanthe ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shallcontinue to maintain the existing MRP in accordance with paragraph 13 (2)of the DPCO, 2013.

(e) Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO.2013 then suchexisting manufacturer shall apply for prior price approval of such newdrug to the NPPA in Form Iasspecified under schedule-ll of the DPCO, 2013.



National Pharmaceutical Pricing Authority :Price Notification Page 2of2

furnish information to the NPPA, in respect ofdiscontinuation ofthe production and / or import ofschedulesformulation in Form-IV of scheduled-ll of the DPCO, 2013 at least six months prior to the indenteddate of discontinuation.


'(h) Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) ofthe above table in this notification, the price order(s) if any, issued prior to the above said date ofnotification, stand withdrawn.

PN/133/1/2013/F





http://www.nppaindia.nic.in/ceiling/press14june13/so1551e-14-6-13 .html 18-Jun-13


4£fc Price Notifications




3S


ORDER

S.0.1552(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government ofIndia in theMinistry ofChemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusiveof local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in'column (2) of the said Table with the strength and unit specified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table



CeilingPrice

(Rs.)

(D (2) (3) (4) (5)Promethazine Syrup 5mg/5ml 1ml 0.21

NOTE

(a)

(b)

(c)

(d)

(e)

'(f)'

The manufacturers of above mentioned scheduled formulations having maximum retail price higherthan the ceiling price specified in column (5) of the table hereinabove, shall revise the MRP to anamount not exceeding the ceiling price plus local taxes, wherever applicable in accordance withparagraph 13 (1) and 24 of the DPCO,2013.


The ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inaccordance with the ceiling price specified in column (5) of the above table as per provisionscontained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issuea price list in Form-V as per the paragraph 24 (2) of the DPCO, 2013.


Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO 2013 then suchexisting manufacturer shall apply for prior price approval ofsuch new drug to the NPPA in Form Iasspecified under schedule-ll of the DPCO, 2013.

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA inrespect of production / import and sale of scheduled formulation in Form-Ill of scheduled-ll of theDPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall


National Pharmaceutical Pricing Authority : Price Notification Page 2ot2

•furnish information to the NPPA, in respect ofdiscontinuation of the production and / or import ofschedulesformulation in Form-IV of scheduled-ll of the DPCO, 2013 at least six months prior to the indenteddate of discontinuation.



PN/133/1/2013/F






National Pharmaceutical Pricing Authority; Price Notification Page 1 of2

;% Price [\Iotifications




3v


ORDER

S.0.1553(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusiveof local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) ofthe said Table with the strength and unit specified respectively in the correspondinq entries incolumns (3) and (4) thereof:

Table



CeilingPrice

(Rs.)

d) (2) (3) (4) (5)1 Paracetamol Injection 150mg/ml 1ml 3.29

NOTE

(a)

(b)

(c)

(d)

(e)

(f)





Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO 2013 then suchexisting manufacturer shall apply for prior price approval of such new drug to the NPPA in Form Iasspecified under schedule-ll of the DPCO, 2013.

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA inS °Lp0roduction 'import and sale of schedu|ed formulation in Form-Ill of scheduled-ll of theDPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall






PN/133/1/2013/F







Price Notifications





ORDER

S.0.1554(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusiveof local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) of the said Table with the strength and unit specified respectively in the correspondinq entries incolumns (3) and (4) thereof:

Table


Formulation Strength UnitCeilingPrice

(Rs.)

(D (2) (3) (4) (5)1 Paracetamol Syrup 125mg/5ml 1ml 0.33

NOTE

(a)

(b)

'(c)

(d)

(e)

(0




All the existing manufacturers of above mentioned scheduled formulations having MRP lower thanthe ceiling price specified in column (5) in the above table plus local taxes asapplicable if any shallcontinue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013'.

Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO 2013 then suchexisting manufacturer shall apply for prior price approval of such new druq to the NPPA in Form Iasspecified under schedule-ll of the DPCO, 2013.

The manufacturers of above said scheduled formulation shall furnish quarterly return to the NPPA in!^S? °LPo°dAUCti0n 'import and sale of scheduled formulation in Form-Ill of scheduled-ll of theDPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall




,(g) The manufacturer not complying with the ceiling price and notes specified hereinabove in thisnotification, shall be liable to deposit overcharged amount along with the interest thereon under theprovisions of the Drugs (Prices Control) Order, 2013 read with the Essential Commodities Act, 1955.


PN/133/1/2013/F






National Pharmaceutical Pricing Authority :Price Notification

Price Notifications


Government of India



Page 1 of2

34


ORDER

S.0.1555(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Governmentof India in the

.Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein belowas ceiling prices exclusiveof local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) of the said Table with the strength and unit specified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table



CeilingPrice

(Rs.)

(1) (2) (3) |I (4) || (5) |1 Paracetamol Tablets 500mg 1 Tab. 0.94

NOTE:

(a) The manufacturers ofabove mentioned scheduled formulations having maximum retail price higherthan the ceiling price specified in column (5) of the table hereinabove, shall revise the MRP to anamount not exceeding the ceiling price plus local taxes, wherever applicable in accordance withparagraph 13 (1) and 24 of the DPCO.2013.



(d) All the existing manufacturers ofabove mentioned scheduled formulations having MRP lower thanthe ceiling price specified in column (5) in theabove table plus local taxes as applicable, if any, shallcontinue to maintain the existing MRP in accordance with paragraph 13 (2)of the DPCO, 2013.




National Pharmaceutical Pricing Authority :Price Notification Page 2of2


(g) The manufacturer not complying with the ceiling price and notes specified hereinabove in thisnotification, shall be liable to deposit overcharged amount along with the interest thereon under theprovisions of the Drugs (Prices Control) Order, 2013 read with the Essential Commodities Act 1955


PN/133/1/2013/F







g^ Price Notifications


Government of India



Page 1 of

37


ORDER

S.O.1556(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusiveof local tax applicable, ifany in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) of the said Table with the strength and unit specified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table



CeilingPrice

(Rs.)

(D (2) (3) ' (4) (5)1 Paracetamol Suppository 80mg 1 Suppository 4.88

NOTE :





(e) Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO.2013 then suchexisting manufacturer shall applyfor prior price approval of such new drug to the NPPA in Form Iasspecified under schedule-ll of the DPCO, 2013.

(f) The manufacturers ofabove said scheduled formulation shall furnish quarterly return to the NPPA, inrespect of production / import and sale of scheduled formulation in Form-Ill of scheduled-ll of theDPCO, 2013. Any manufacturer intending to discontinue above said scheduled formulation shall






PN/133/1/2013/F





http://www.nppaindia.nic.in/ceiling/pressl4june13/so1556'e-14-6-13.html 18-Jun-13


^ Price Notifications




Page 1 of2

3a


ORDER

S.0.1557(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theMinistry ofChemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) ofthe table herein below as ceiling prices exclusiveof local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) of the said Table with the strength and unit specified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table



CeilingPrice

(Rs.)

d) (2) (3) (4) (5)1 Paracetamol Suppository 170mg 1 Suppository 5.99

NOTE :




(d) All the existing manufacturers of above mentioned scheduled formulations having MRP lower thanthe ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shallcontinue to maintain the existing MRP in accordance with paragraph 13 (2) ofthe DPCO, 2013.

(e) Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO.2013 then suchexisting manufacturer shall apply for prior price approval of such new drug to the NPPA in Form Iasspecified under schedule-ll of the DPCO, 2013.







PN/133/1/2013/F

F No 8(1 )/?013/D P /NPPA-Div II






fySfe Price Notifications


Government of India



3 1


ORDER

S.0.1558(E) - In exercise ofthe powers, conferred by paragraph 4, 11 and 14 ofthe Drugs (Prices Control)•Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) ofthe table herein below as ceiling prices exclusiveof local tax applicable, if any in respectofthe Scheduled formulations specified in the corresponding entry incolumn (2) ofthe said Table with the strength and unit specified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table


FormulationStrength. Unit

CeilingPrice

(Rs.)

(1) (2) (3) (4) (5)1 Fentanyl Injection 50mcg/ml 1 ml 20.26

NOTE:

.(a) The manufacturers ofabove mentioned scheduled formulations having maximum retail price higherthan the ceiling price specified in column (5) of the table hereinabove, shall revise the MRP to anamount not exceeding the ceiling price plus local taxes, wherever applicable in accordance withparagraph 13 (1) and 24 of the DPCO.2013.


(c) The ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inaccordance with the ceiling price specified in column (5) of the above table as per provisionscontained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issuea price list in Form-V as per the paragraph 24 (2) of the' DPCO, 2013.

(d) All the existing manufacturers of above mentioned scheduled formulations having MRP lower thanthe ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shallcontinue to maintain the existing MRP in accordance with paragraph 13 (2) ofthe DPCO, 2013.

(e) Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as perparagraph 2 (u) of DPCO.2013 then suchexisting manufacturer shall apply for prior price approval ofsuch new drug to the NPPA in Form Iasspecified under schedule-ll of the DPCO, 2013.







P N/133/1/2013/F







Price Notifications


Government of India



Page 1 of2


ORDER

S.O.1559(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusiveof local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) of the said Table with the strength and unit specified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table



CeilingPrice

(Rs.)

(D (2) (3) (4) (5)

1 Colchicine Tablets 0.5mg 1 Tab. 2.88

NOTE:





(e) Where an existing manufacturer of scheduled formulation with dosage or strength or both asspecified in the above table, launches a new drug as per paragraph 2 (u) of DPCO.2013 then suchexisting manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I asspecified under schedule-ll of the DPCO, 2013.






,(h) Consequent to the issue of ceiling price of the scheduled formulation as specified in column (2) ofthe above table in this notification, the price order(s) if any, issued prior to the above said date ofnotification, stand withdrawn.

PN/133/1/2013/F







Price Notifications


Government of India



Page 1 of2

HI


ORDER

S.O.1560(E) - In exercise of the powers, conferred by paragraph 4, 11 and 14 of the Drugs (Prices Control)Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in theMinistry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred asNPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusiveof local tax applicable, ifany in respect of the Scheduled formulations specified in the corresponding entry incolumn (2) of the said Table with the strength and unit specified respectively in the corresponding entries incolumns (3) and (4) thereof:

Table



CeilingPrice

(Rs.)

(1) (2) (3) (4) (5)

1 Azathioprine Tablets 50mg 1Tab. 9.89

NOTE :


(b) The manufacturers may add local taxes only if they have paid actually to the Government on theceiling price mentioned in the column (5) of the above fable.

(c) The ceiling price for a pack of the schedule formulation shall be arrived at by the manufacturer inacco

national pharmaceutical pricing authority :price ...€¦ · nppa in its 132th authority meeting...

Documents